Our real-world study confirms that, compared to metformin, the antidiabetic non-insulin drugs SGLT-2i and GLP-1 RAs confer extra benefits when administered in standard-of-care treatment and in association with CV drugs used for the treatment of High BP (HBP), such as BB, CCB, ACEI, or ARB, or for the treatment of dyslipidaemia, such as statins. Here, GLP1R is linked to inherited lipid metabolism disorder.